<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
	<atom:link href="http://prostatecancerinfolink.net/feed/" rel="self" type="application/rss+xml" />
	<link>http://prostatecancerinfolink.net</link>
	<description></description>
	<lastBuildDate>Sat, 28 Jan 2012 01:13:09 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='prostatecancerinfolink.net' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://s2.wp.com/i/buttonw-com.png</url>
		<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
		<link>http://prostatecancerinfolink.net</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="http://prostatecancerinfolink.net/osd.xml" title="THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK" />
	<atom:link rel='hub' href='http://prostatecancerinfolink.net/?pushpress=hub'/>
		<item>
		<title>AHRQ responds to letter from Prostate Cancer Roundtable</title>
		<link>http://prostatecancerinfolink.net/2012/01/27/ahrq-responds-to-letter-from-prostate-cancer-roundtable/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/27/ahrq-responds-to-letter-from-prostate-cancer-roundtable/#comments</comments>
		<pubDate>Fri, 27 Jan 2012 22:10:25 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[screening]]></category>
		<category><![CDATA[testing]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14883</guid>
		<description><![CDATA[Members of the Prostate Cancer Roundtable have received a letter from the Agency for Healthcare Research and Quality (AHRQ) addressing issues raised by the Roundtable members about the draft USPSTF recommendations on use of the PSA test in screening for risk of prostate cancer. The letter from Dr. Carolyn Clancy makes no comments or commitments [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14883&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/27/ahrq-responds-to-letter-from-prostate-cancer-roundtable/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>The walnuts are back in vogue (at least with mice)</title>
		<link>http://prostatecancerinfolink.net/2012/01/26/the-walnuts-are-back-in-vogue-at-least-with-mice/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/26/the-walnuts-are-back-in-vogue-at-least-with-mice/#comments</comments>
		<pubDate>Thu, 26 Jan 2012 15:16:37 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[walnut]]></category>

		<guid isPermaLink="false">http://talkaboutprostatecancer.wordpress.com/?p=14878</guid>
		<description><![CDATA[According to a media release we received yesterday, a new paper in the British Journal of Nutrition suggests that &#8220;walnuts may help to prevent prostate cancer risk.&#8221; Of course what the study actually shows is that &#8230; prostate tumors in mice fed the human equivalent of three ounces per day of walnuts were approximately 50% [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14878&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/26/the-walnuts-are-back-in-vogue-at-least-with-mice/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Sebelius has NOT overruled USPSTF recommendation after all</title>
		<link>http://prostatecancerinfolink.net/2012/01/25/sebelius-has-not-overruled-uspstf-recommendation-after-all/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/25/sebelius-has-not-overruled-uspstf-recommendation-after-all/#comments</comments>
		<pubDate>Wed, 25 Jan 2012 14:42:16 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[recommendation]]></category>
		<category><![CDATA[screening]]></category>
		<category><![CDATA[USPSTF]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14867</guid>
		<description><![CDATA[For our US-based readers &#8230; It appears that Rep. Kucinich&#8217;s statements on his web site (reported on this web site a few days ago) are something of a political simplification of reality. On December 9, 2011, Secretary Sebelius sent this letter to Rep. Kucinich and his colleagues. The letter contains the following statement (in specific reference [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14867&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/25/sebelius-has-not-overruled-uspstf-recommendation-after-all/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>The value of MRI prior to surgery as a treatment for localized prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/01/25/the-value-of-mri-prior-to-surgery-as-a-treatment-for-localized-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/25/the-value-of-mri-prior-to-surgery-as-a-treatment-for-localized-prostate-cancer/#comments</comments>
		<pubDate>Wed, 25 Jan 2012 14:21:32 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[endorectal]]></category>
		<category><![CDATA[MRI]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[surgery]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14862</guid>
		<description><![CDATA[A recent media release from the Radiological Society of North America (RSNA) is headed, &#8220;Preoperative MRU may reduce risk of nerve damage in prostate cancer surgeries&#8221; &#8230; and this is absolutely true. The problem, however, is that it is only appears to be true for about a quarter of all the men undergoing surgery, so [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14862&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/25/the-value-of-mri-prior-to-surgery-as-a-treatment-for-localized-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Dutasteride as a single agent for low-risk prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/01/24/dutasteride-as-a-single-agent-for-low-risk-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/24/dutasteride-as-a-single-agent-for-low-risk-prostate-cancer/#comments</comments>
		<pubDate>Wed, 25 Jan 2012 01:59:30 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dutasteride]]></category>
		<category><![CDATA[low risk]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[progression]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14852</guid>
		<description><![CDATA[According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®). Fleshner et al. conducted a multi-center, randomized, double-blind, placebo-controlled trial (the REDEEM trial) in men aged between 48 and 82 years who [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14852&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/24/dutasteride-as-a-single-agent-for-low-risk-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>5</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Tasquinimod + cabazitaxel in heavily pre-treated men with mCRPC</title>
		<link>http://prostatecancerinfolink.net/2012/01/23/tasquinimod-cabazitaxel-in-heavily-pre-treated-men-with-mcrpc/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/23/tasquinimod-cabazitaxel-in-heavily-pre-treated-men-with-mcrpc/#comments</comments>
		<pubDate>Mon, 23 Jan 2012 14:11:16 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[cabazitaxel]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[Jevtana]]></category>
		<category><![CDATA[mCRPC]]></category>
		<category><![CDATA[metastatic]]></category>
		<category><![CDATA[taquinimod]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14846</guid>
		<description><![CDATA[According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC). The media release from Active Biotech says that this study is [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14846&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/23/tasquinimod-cabazitaxel-in-heavily-pre-treated-men-with-mcrpc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Has Sebelius overruled USPSTF recommendation on PSA screening?</title>
		<link>http://prostatecancerinfolink.net/2012/01/21/has-sebelius-overruled-uspstf-recommendation-on-psa-screening/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/21/has-sebelius-overruled-uspstf-recommendation-on-psa-screening/#comments</comments>
		<pubDate>Sat, 21 Jan 2012 12:28:25 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[rfisk]]></category>
		<category><![CDATA[screening]]></category>
		<category><![CDATA[testing]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14841</guid>
		<description><![CDATA[According to an announcement on the web site of Congressmen Dennis Kucinich late yesterday, HHS Secretary Kathleen Sebelius has agreed to overule the draft recommendation issued by the U.S. Preventive Services Task Force (USPSTF) related to the use of PSA testing as a means to detect prostate cancer. The exact implications of this are not [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14841&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/21/has-sebelius-overruled-uspstf-recommendation-on-psa-screening/feed/</wfw:commentRss>
		<slash:comments>9</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>New Jersey passes legislation against USPSTF recommendation on prostate cancer screening</title>
		<link>http://prostatecancerinfolink.net/2012/01/20/new-jersey-passes-legislation-against-uspstf-recommendation-on-prostate-cancer-screening/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/20/new-jersey-passes-legislation-against-uspstf-recommendation-on-prostate-cancer-screening/#comments</comments>
		<pubDate>Fri, 20 Jan 2012 15:36:30 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14839</guid>
		<description><![CDATA[According to a media release issued late yesterday by the American Urological Association, Governor Christie has signed legislation in New Jersey that asks &#8220;the Congress of the United States to seek the withdrawal of the United States Preventative Services Task Force recommendation against prostate-specific antigen-based screening for prostate cancer for men in all age groups.&#8221; [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14839&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/20/new-jersey-passes-legislation-against-uspstf-recommendation-on-prostate-cancer-screening/feed/</wfw:commentRss>
		<slash:comments>12</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Sequencing of treatment with new therapeutic agents for advanced prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/01/19/sequencing-of-treatment-with-new-therapeutic-agents-for-advanced-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/19/sequencing-of-treatment-with-new-therapeutic-agents-for-advanced-prostate-cancer/#comments</comments>
		<pubDate>Fri, 20 Jan 2012 00:44:04 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[advanced]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[new]]></category>
		<category><![CDATA[sequencing]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14835</guid>
		<description><![CDATA[The January 2012 issue of Oncology contains an open access, full-text article on the future sequencing of the recently approved and potentially new drugs that are or should soon be available for the treatment of advanced prostate cancer. Because this full text article by Crawford and Flaig is available on line, we simply refer readers [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14835&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/19/sequencing-of-treatment-with-new-therapeutic-agents-for-advanced-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>The future of focal therapy</title>
		<link>http://prostatecancerinfolink.net/2012/01/19/the-future-of-focal-therapy/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/19/the-future-of-focal-therapy/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 12:52:44 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[con]]></category>
		<category><![CDATA[focal therapy]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[pro]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14833</guid>
		<description><![CDATA[Two &#8220;pro&#8221; and &#8220;con&#8221; commentaries appeared on line this week in the Journal of Urology under the heading &#8220;Focal therapy will become standard treatment for localized prostate cancer.&#8221; In the first of the two articles, Joel Nelson, who is chairman of the Department of Urology at the University of Pittsburgh here in the USA, argues [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14833&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/19/the-future-of-focal-therapy/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>An update on views about the USPSTF recommendation and prostate cancer screening</title>
		<link>http://prostatecancerinfolink.net/2012/01/18/an-update-on-views-about-the-uspstf-recommendation-and-prostate-cancer-screening/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/18/an-update-on-views-about-the-uspstf-recommendation-and-prostate-cancer-screening/#comments</comments>
		<pubDate>Wed, 18 Jan 2012 21:38:44 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14829</guid>
		<description><![CDATA[Apparently, earlier this week, Congressmen Runyan and Baca (the co-chairmen of the Congressional Prostate Cancer Task Force) sent a letter to Secretary Sebelius about prostate cancer screening. The entire text of this letter can be read if you just click here. The general gist of this letter &#8212; targeted to head off the recent recommendation [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14829&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/18/an-update-on-views-about-the-uspstf-recommendation-and-prostate-cancer-screening/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Will active surveillance save us money in management of prostate cancer?</title>
		<link>http://prostatecancerinfolink.net/2012/01/18/will-active-surveillance-save-us-money-in-management-of-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/18/will-active-surveillance-save-us-money-in-management-of-prostate-cancer/#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:29:05 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[active surveillance]]></category>
		<category><![CDATA[cost]]></category>
		<category><![CDATA[cost-effectiveness]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14822</guid>
		<description><![CDATA[From a health economics point of view, prostate cancer costs a lot of money every year &#8212; because a lot of men get diagnosed and treated. However, data on the cost-effectiveness of active surveillance compared to immediate treatment are still few and far between. Keegan et al. have just published estimates suggesting that active surveillance [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14822&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/18/will-active-surveillance-save-us-money-in-management-of-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Trip&#8217;s trip &#8230; 10 years of battling metastatic prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/01/17/trips-trip-10-years-of-battling-metastatic-prostate-cacner/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/17/trips-trip-10-years-of-battling-metastatic-prostate-cacner/#comments</comments>
		<pubDate>Wed, 18 Jan 2012 02:52:20 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[metastatic]]></category>
		<category><![CDATA[remission]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14818</guid>
		<description><![CDATA[In 2001, when he was just 49 years old, Ward &#8220;Trip&#8221; Casscells experienced lower back pain that became progressively worse. Then, he felt a lump in his abdominal area. He had an aggressive, metastatic prostate cancer. Over  the past 10 years, Trip has undergone numerous treatments for his disease. He will cheerfully tell you, “I [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14818&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/17/trips-trip-10-years-of-battling-metastatic-prostate-cacner/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Self-referral and the role of IMRT in treatment of prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/01/17/self-referral-and-the-role-of-imrt-in-treatment-of-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/17/self-referral-and-the-role-of-imrt-in-treatment-of-prostate-cancer/#comments</comments>
		<pubDate>Tue, 17 Jan 2012 20:10:59 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[IMRT]]></category>
		<category><![CDATA[motive]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[self-referral]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14813</guid>
		<description><![CDATA[The issue of whether some urology practices are investing in equipment capable of delivering intensity-modulated radiation therapy (IMRT) with financial motives is back on the front burner again. An article in today&#8217;s Baltimore Sun pretty much accuses a particular urology practice of investing in IMRT equipment for financial gain and self-referring patients for IMRT rather [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14813&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/17/self-referral-and-the-role-of-imrt-in-treatment-of-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>&#8220;Peripheral&#8221; androgen deprivation for men with a rising PSA after surgery and/or radiation therapy</title>
		<link>http://prostatecancerinfolink.net/2012/01/16/peripheral-androgen-deprivation-for-men-with-a-rising-psa-after-surgery-andor-radiation-therapy/</link>
		<comments>http://prostatecancerinfolink.net/2012/01/16/peripheral-androgen-deprivation-for-men-with-a-rising-psa-after-surgery-andor-radiation-therapy/#comments</comments>
		<pubDate>Mon, 16 Jan 2012 14:29:09 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[androgen]]></category>
		<category><![CDATA[deprivation]]></category>
		<category><![CDATA[PAD]]></category>
		<category><![CDATA[peripheral]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14805</guid>
		<description><![CDATA[What is the best type of treatment to offer a man after primary and (perhaps) appropriate secondary forms of treatment leave him with a rising PSA? Historically, the standard &#8220;next step&#8221; for a man with such a rising PSA (biochemical progression) after first-line radiation therapy or first-line surgery and second-line radiation therapy has been androgen [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14805&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/01/16/peripheral-androgen-deprivation-for-men-with-a-rising-psa-after-surgery-andor-radiation-therapy/feed/</wfw:commentRss>
		<slash:comments>7</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
	</channel>
</rss>
